+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antibody Drug Conjugates Market 2019-2025

  • PDF Icon


  • June 2019
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4803471
Global Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Brain Tumor, Blood Cancer, Breast Cancer, Ovarian Cancer, and Lung Cancer), By Technology (Cleavable Linker and Non-cleavable Linker) Forecast, 2019-2025.

Antibody drug conjugates is an effective biopharmaceutical drug developed for the treatment of cancer. These drugs are further intended to target cancer cells directly without harming or destroying other normal cells. It consists of three major parts, namely, a specific body for binding, an antigen that has a fixed expression on normal cells; a cytotoxic agent to eliminate cancer cell in the body; and the chemical linker to fix the cytotoxic agent to the antibody. One of the key advantages of antibody drug conjugates is that it assists in bringing together the finest characteristics of both chemotherapy's cytotoxin potential as well as antibodies. The global antibody drug conjugate market is bifurcated into applications and technology. The applications of antibody drug conjugate include blood cancer, breast cancer, ovarian cancer, lungs cancer, and others. The two technologies available in the market includes cleavable linker and non-cleavable linker.

There were majorly four antibody drug conjugates available in the market, namely Adcetris, Besponsa, Kadcyla, and Mylotarg. Owing to the demand for improved technology and appropriate targeting, antibody drug conjugates has been gaining traction and currently there are many antibody drug conjugates at the development stage. This can be one of the key factors fueling the growth of the market in the near future. However, the antibody drug conjugates market is still at a fancy stage and only four antibody drug conjugates have been approved by the US FDA. The R&D activities in the antibody drug conjugate are a prominent factor motivating the growth of antibody drug conjugate market across the globe.

The global antibody drug conjugates market is further analyzed on the basis of geographical regions, including North America, Europe, Asia-Pacific, and Rest of the World. North America shows significant growth in the global market, owing to the factors such as well-established healthcare infrastructure and government regulations regarding patient's safety and security. Moreover, the high presence of antibody drug conjugates manufacturers contributes a significant share in the market growth. European is projected to exhibit the considerable growth rate in the market. This is mainly due to certain factors such as rising cancer incidences, changing lifestyles, high investments in R&D, and growth in biomedical industry.

The key players operating in the global antibody drug conjugates market are AbbVie Inc., Genentech, Inc., Bayer AG, Concortis Biotherapeutics, Pfizer Inc., Seattle Genetics, Inc., and Oxford BioTherapeutics Ltd., among others. These companies look forward to the expansion and innovation of the drugs by adopting various stringent activities such as merger and acquisition, product launch, and partnership and collaborations, among others. These activities assist companies in generating significant revenue from the market.

Research Methodology

The market study of the global antibody drug conjugates market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

Financial reports of companies involved in the market
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue

The report is intended for biotechnology companies, medical laboratories, investment companies, and government organizations provide sector for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Antibody Drug Conjugates Market Research and Analysis by Application
2. Global Antibody Drug Conjugates Market Research and Analysis by Technology

The Report Covers

Comprehensive research methodology of the global antibody drug conjugates market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global antibody drug conjugates market.

Insights about market determinants which are stimulating the global antibody drug conjugates market.

Detailed and extensive market segments with regional distribution of forecast revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Genentech, Inc., a company of F. Hoffmann La-Roche Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Seattle Genetics, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Oxford BioTherapeutics Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Antibody Drug Conjugates Market by Application
5.1.1. Blood Cancer
5.1.2. Breast Cancer
5.1.3. Ovarian Cancer
5.1.4. Lung Cancer
5.1.5. Others (Brain Tumor and Cervical Cancer)
5.2. Global Antibody Drug Conjugates Market by Technology
5.2.1. Cleavable Linker
5.2.2. Non-cleavable Linker
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Astellas Pharma Inc.
7.3. Bayer AG
7.4. Celldex Therapeutics, Inc.
7.5. Concortis Biotherapeutics
7.6. Creative Biolabs, Inc.
7.7. Genentech, Inc., a company of F. Hoffmann La-Roche Ltd.
7.8. Heidelberg Pharma AG
7.9. ImmunoGen, Inc.
7.10. Immunomedics, Inc.
7.11. Lonza Group
7.12. Mersana Therapeutics, Inc.
7.13. Oxford BioTherapeutics Ltd.
7.14. Pfizer Inc.
7.15. Progenics Pharmaceuticals Inc.
7.16. Seattle Genetics, Inc.
7.17. Sorrento Therapeutics, Inc.
7.18. Synthon Holding B.V.
7.19. Takeda Pharmaceutical Co. Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Celldex Therapeutics, Inc.
  • Concortis Biotherapeutics
  • Creative Biolabs, Inc.
  • Genentech, Inc., a company of F. Hoffmann La-Roche Ltd.
  • Heidelberg Pharma AG
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Lonza Group
  • Mersana Therapeutics, Inc.
  • Oxford BioTherapeutics Ltd.
  • Pfizer Inc.
  • Progenics Pharmaceuticals Inc.
  • Seattle Genetics, Inc.
  • Sorrento Therapeutics, Inc.
  • Synthon Holding B.V.
  • Takeda Pharmaceutical Co. Ltd.